Oligosaccharide-Modified GLP-1 Peptides for Blood Sugar Control

Solution Overview

Problem

Current GLP-1 peptides have a short half-life in the blood, limiting their therapeutic potential due to rapid clearance, and modifications such as PEGylation can lead to adverse reactions and antibody formation, while existing oligosaccharide chain additions are not uniform and lack stability.

Innovation Solution

Development of an oligosaccharide chain added GLP-1 peptide with specific amino acid substitutions at positions 18, 20, 22, 26, 30, 34, or 36, using oligosaccharide chains like disialo or hyaluronic acid, linked directly or via a linker, to enhance stability and activity.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Duration of action of moving object

If PEGylation is used to prolong half-life, then stability and duration of action are improved, but adverse reactions and antibody formation occur

Engineering Contradiction:
Core Design Contradiction:
Duration of action of moving objectVSObject-affected harmful factors

Solution Approach 1:

The invention changes the chemical nature of the conjugate from synthetic PEG to natural oligosaccharide chains, altering the parameter of biocompatibility while maintaining the duration-extending function. The oligosaccharide chains are metabolizable unlike PEG, eliminating accumulation and adverse reactions while still prolonging half-life to at least 1 hour

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

The invention creates a composite structure by conjugating oligosaccharide chains to the GLP-1 peptide backbone, combining the therapeutic activity of GLP-1 with the stability-enhancing properties of oligosaccharide moieties, achieving both prolonged duration and reduced immunogenicity

Inventive Principle:
Principle #40Composite materials

2Duration of action of moving object

If oligosaccharide chains are added to prolong half-life, then stability is improved, but uniformity and manufacturing precision are insufficient

Engineering Contradiction:
Core Design Contradiction:
Duration of action of moving objectVSManufacturing precision

Solution Approach 1:

The invention applies oligosaccharide chains at specific local positions on the GLP-1 peptide (amino acid positions 6, 11, 16, 21, 26, or 31), ensuring consistent and controlled modification sites that improve manufacturing uniformity while maintaining the stability benefits

Inventive Principle:
Principle #3Local quality

Solution Approach 2:

The oligosaccharide chains are introduced as discrete, defined segments with specific structures (such as disialo chains or hyaluronic acid oligomers) rather than heterogeneous polymers, enabling precise control over the conjugate's physical and chemical properties for consistent manufacturing

Inventive Principle:
Principle #1Segmentation

3Duration of action of moving object

If big hyaluronic acid molecules are used to prolong half-life, then stability is improved, but structural uniformity and manufacturing precision deteriorate

Engineering Contradiction:
Core Design Contradiction:
Duration of action of moving objectVSManufacturing precision

Solution Approach 1:

Instead of using large, heterogeneous hyaluronic acid molecules, the invention segments the hyaluronic acid into smaller, defined oligomer units with controlled molecular weights and structures, enabling precise manufacturing while maintaining the stability-prolonging effect

Inventive Principle:
Principle #1Segmentation

Solution Approach 2:

The invention changes the molecular weight parameter of the hyaluronic acid component from high molecular weight (200 KDa) to controlled oligomer sizes, improving solubility, uniformity, and manufacturing precision while retaining the ability to prolong half-life through controlled degradation

Inventive Principle:
Principle #35Parameter changes

Data Source

PatentUS8765669B2Glycosylated GLP-1 peptide
Publication Date: 2014.07.01
  • US8765669B2 patent drawing
  • US8765669B2 patent drawing
  • US8765669B2 patent drawing

AI summary

Oligosaccharide chain added GLP-1 peptides are more stable in blood and more active in controlling blood-sugar levels than GLP-1 peptides without added oligosaccharides. Oligosaccharide chain added GLP-1 peptides having GLP-1 activity include at least one or at least two amino acids each substituted with an oligosaccharide chain added amino acid in GLP-1; a peptide having the amino acid sequence of GLP-1 with deletion, substitution or addition of one or several amino acids; or a GLP-1 analog. Oligosaccharide chain added GLP-1 peptides with at least one amino acid substituted with an oligosaccharide chain added amino acid include an oligosaccharide chain with oligo hyaluronic acid. Oligosaccharide chain added amino acids include oligosaccharide chains attached to amino acids via linkers.